# **Neurosteroid modulation of respiratory rhythm in rats during the perinatal period**

# Jun Ren and John J. Greer

*Department of Physiology, Division of Neuroscience, 513 HMRC, University of Alberta, Edmonton Alberta, Canada T6G 2S2*

**Neurosteroids regulate neuronal excitability and are expressed at particularly high levels in the CNS during the perinatal period. Further, neurosteroid levels are increased by a variety of stressors including hypoxia, asphyxia, parturition, ethanol exposure and infection. One mechanism by which neurosteroids regulate neuronal activity is by negative or positive modulation of GABA<sup>A</sup> receptor function. Perinatal respiration is strongly modulated by GABAergic synaptic drive, and GABA release is increased during hypoxia to contribute to hypoxia-induced depression of neonatal ventilation. Here, we use** *in vitro* **and** *in vivo* **rat models** to test the hypothesis that GABA<sub>A</sub> receptor-mediated modulation of perinatal respiration is **markedly influenced by the presence of neurosteroids. The principal finding of this study** was that the efficacy of GABA<sub>A</sub> receptor-mediated modulation of respiratory membrane **potential and rhythmogenesis is markedly enhanced by allopregnanolone and depressed by dehydroepiandrosterone sulphate. These data demonstrate that the modulation of breathing via GABA<sup>A</sup> receptor activation will be determined by the overall balance of negative and positive neurosteroid modulators within respiratory nuclei. This adds a level of complexity that must be considered when examining the depression of breathing in mammals associated with various behavioural states and pathogenic conditions such as apnoea and sudden death suspected to be associated with central respiratory dysfunction.**

(Received 2 March 2006; accepted after revision 6 May 2006; first published online 11 May 2006) **Corresponding author**J. J. Greer: University of Alberta, Department of Physiology, 513 HMRC, Edmonton, AB, Canada T6G 2S2. Email: john.greer@ualberta.ca

The frequency and amplitude of respiratory rhythmic drive is dynamically regulated to meet the varied demands for ventilation. In particular, rhythmogenesis generated within a key area of the ventrolateral medulla, the preBötzinger complex (preBötC), is modulated by synaptic drive from multiple neurotransmitter systems (reviewed in Rekling & Feldman, 1998). An important inhibitory input arises from GABAergic neurons (Johnson *et al.* 1996; Shao & Feldman, 1997; Brockhaus & Ballanyi, 1998; Ritter & Zhang, 2000). Further, the levels of GABA released are increased during hypoxia, and contribute to hypoxia-induced depression of neonatal ventilation (Huang *et al.* 1994). In a recent study (Ren & Greer, 2006), we demonstrated the age-dependent changes of GABA<sub>A</sub> receptor-mediated actions on respiratory rhythmogenesis during the perinatal period in the rat. Here, we extend upon that work by testing the hypothesis that  $GABA_A$ receptor-mediated modulation of perinatal respiration can be profoundly influenced by the presence of neurosteroids.

Steroid hormones and their derivatives regulate neuronal excitability and function (Akwa *et al.* 1991; Majewska, 1992; Mellon, 1994; Baulieu & Robel, 1996, 1998; Baulieu, 1997; Joels, 1997; Jung-Testas & Baulieu, 1998). These actions are mediated by modulating neurotransmitter receptor function, ion channel kinetics, and directly via binding to steroid receptors located on neuronal membranes. Neurosteroids within the CNS arise from two general sources. There are neurosteroids that are synthesized within the CNS from cholesterol or steroid hormone precursors (e.g. pregnenolone, allopregnanolone, progesterone, dehydroepiandorosterone, oestradiol,  $5\alpha$ -dihydrotesterone), and those that arrive via the circulation (e.g. testosterone). The level of neurosteroid synthesis in the CNS is particularly high during the perinatal period (Brown & Papadopoulos, 2001; Mellon & Vaudry, 2001) and increases during periods of physiological stress (e.g. hypoxia, parturition, infection; Barbaccia *et al.* 2001). Neurosteroids, depending on their structure, can act as either negative or positive modulators of GABAA receptor function (Park-Chung *et al.* 1999). Thus, there is potential for a neurosteroid– $GABA_A$ receptor interaction, with important implications for the control of perinatal breathing. Specifically, the net effect

of GABAergic synaptic input to respiratory neuronal populations could vary markedly depending on the type and concentration of neurosteroids during a given state. In this study, we examined the actions of allopregnanolone and dehydroepiandrosterone sulphate (DHEAS) on the spontaneous respiratory drive generated by *in vitro* models and *in vivo*. These two neurosteroids are prevalent in the perinatal CNS and have pronounced modulatory effects on GABA<sub>A</sub> receptor function (Compagnone *et al.* 1995; Nguyen *et al.* 2003).

#### Methods

#### **Brainstem–spinal cord preparations**

Fetal Sprague-Dawley rats (E17–21) were delivered from timed-pregnant dams anaesthetized with halothane (2.5% delivered in 95%  $O_2$  and 5%  $CO_2$ ) and maintained at 37◦C by radiant heat, following procedures approved by the Animal Welfare Committee at the University of Alberta. The timing of pregnancies was determined from the appearance of sperm plugs in the breeding cages. The ages of fetuses were confirmed by comparison of their crown–rump length measurements with those published by Angulo Y González, 1932). Newborn rats were anaesthetized by inhalation of metofane (2–3%). Embryos and newborns were decerebrated, and the medulla–spinal cord dissected following procedures similar to those established (Smith *et al.* 1990; Greer *et al.* 1992). The neuraxis was continuously perfused at  $27 \pm 1$ °C (perfusion rate 5 ml min<sup>−</sup>1; chamber volume 1.5 ml) with modified Krebs solution that contained the following (mm): 128 NaCl, 3.0 KCl, 1.5 CaCl<sub>2</sub>, 1.0 MgSO<sub>4</sub>, 23.5 NaHCO<sub>3</sub>, 0.5 NaH<sub>2</sub>PO<sub>4</sub>, and 30 p-glucose (equilibrated with  $95\%O_2 - 5\%CO_2$ ).

#### **Medullary slice preparations**

Details of the preparation have been previously described (Smith *et al.* 1991). Briefly, the brainstem–spinal cords isolated from perinatal rats as described above were pinned down, ventral surface upward, on a paraffin-coated block. The block was mounted in the vise of a vibratome bath (VT1000S; Leica, Nussloch, Germany). The brainstem was sectioned serially in the transverse plane starting from the rostral medulla, to within approximately 150  $\mu$ m of the rostral boundary of the preBöt $C$ , as judged by the appearance of the inferior olive. A single transverse slice containing the pre $B$ öt $C$  and more caudal reticular formation regions was then cut  $(500-700 \,\mu m)$  thick), transferred to a recording chamber, and pinned down onto a Sylgard elastomer. The medullary slice was continuously perfused in physiological solution similar to that used for the brainstem–spinal cord preparation except for  $[K^+]_0$ , which was increased to 9 mm to stimulate the spontaneous rhythmic respiratory motor discharge in the medullary slice (Smith *et al.* 1991).

#### **Extracellular recording and analysis**

Recordings of hypoglossal (XII) nerve roots and cervical (C4) ventral roots were made with suction electrodes. Suction electrodes were placed into the XII nuclei and preBötC region of the ventrolateral medulla to record extracellular neuronal population discharge from medullary slice preparations. Signals were amplified, rectified, low-pass filtered, and recorded on a computer using an analog-to-digital converter (Digidata 1322A; Axon Instruments, Union City, CA, USA) and data acquisition software (Clampfit, Axon Instruments). Mean values of respiratory frequency relative to control were calculated pre-, during and post-drug delivery using Matlab software (Mathworks, Inc.). Values of  $EC_{50}$  and IC<sub>50</sub> are defined as the concentration of drug necessary to produce 50% of the maximum mean measured response. Results were expressed as mean ± standard deviation (s.p.). Statistical significance was tested using paired/unpaired difference Student's *t* test (two groups) or one-way RM ANOVA (multiple groups); significance was accepted at *P* values < 0.05.

# **Intracellular recordings from medullary slice preparations**

Patch electrodes were fabricated from thin-walled borosilicate glass (1.5 mm external and 1.12 mm internal diameter; A-M Systems, Everett, WA, USA). The pipette resistances were between 3 and  $5 M<sub>\Omega</sub>$ . All whole-cell patch recordings were obtained from the somata of small neurons within the region of the preBötC, localized ventrolaterally to the pars compacta of the ambiguous nucleus. Neurons were approached under visual control using a microscope equipped with an infrared contrast enhancement system (Axioskop, Zeiss, Oberkochen, Germany). To establish whole-cell recording, additional suction was applied to rupture the underlying plasma membrane. The standard pipette solution contained the following (mm): 140 K-gluconate, 4 NaCl, 1 CaCl<sub>2</sub>, 10 EGTA or BAPTA (10), 10 Hepes, 5 MgATP, and 0.3 Na<sub>3</sub>GTP, pH adjusted to 7.3 with KOH. Whole-cell current-clamp recordings were initially established in modified Krebs solution and performed with an NPI Electronics SEC05LX amplifier (NPI Electronics, Tamm, Germany). All liquid junction potentials were corrected before seal formation with the compensation circuitry of the patch-clamp amplifier. Neurons with resting membrane potentials ( $V$ <sub>rest</sub>) more negative than −40 mV and overshooting action potentials were analysed. Data were digitized with an analog-to-digital interface (Digidata

1322A; Axon Instruments) and analysed with the use of pClamp 9.2 (Axon Instruments).

#### **Pharmacological agents**

The following drugs were used: allopregnanolone ( $5\alpha$ pregnan-3α-ol-20-one), pregnanolone (5β-pregnan-3αol-20-one), alfaxalone (5 $\alpha$ -pregnan-3 $\alpha$ -ol-11,20-dione), allotetrahydrodeoxycorticosterone (3α,21-dihydroxy-5αpregnan-20-one), isopregnanolone (5α-pregnan-3β-ol-20-one), pregnenolone (5-pregnen- $3\beta$ -ol-20-one), 5 $\alpha$ pregnane-3β,20β-diol, 17β-oestradiol, and progesterone, dehydroisoandrosterone (DHEA), DHEAS, bicuculline (free base; soluble in DMSO), muscimol, tetrodotoxin (TTX), ethylene glycol-bis(b-aminoethylether)- *N*,*N*,*N* ,*N* -tetraacetic acid (EGTA), 1,2-bis(2-aminophenoxy)ethane-*N*,*N*,*N* ,*N* -tetraacetic acid tetrapotassium salt (BAPTA). The doses of neurosteroids used were based on similar*in vitro* studies and pharmacological profiles of the  $EC_{50}$  and  $IC_{50}$  (Majewska, 1990; Spivak, 1994; Sousa & Ticku, 1997; Rupprecht & Holsboer, 2000). Drugs were purchased from Sigma (St Louis, MO, USA) or RBI (Oakville, ON, USA). Stock solutions of drugs were prepared as concentrates. All drugs used *in vitro* were dissolved in modified Krebs solution, and the pH adjusted to 7.4. Muscimol (soluble in physiological 0.9% NaCl saline; 0.3–0.5 mg kg<sup>−</sup>1), bicuculline (free base, soluble in DMSO, 0.6–1 mg kg<sup>-1</sup>), allopregnanolone (0.5–4 mg kg<sup>−</sup><sup>1</sup> dissolved in DMSO; Gizerian *et al.* 2004), and DHEAS 10 mg kg<sup>−</sup><sup>1</sup> dissolved in DMSO; Hoffman *et al.* 2003) were administered i.p. *in vivo*.

#### *In vivo* **neonatal plethysmographic measurements**

Whole-body plethysmographic measurements of frequency and depth of breathing were made from E20–P4 unanaesthetized rats of either sex. Pressure changes associated with perinatal rat breathing were measured using a 27 ml whole-body plethysmograph chamber, a pressure transduced (model DP103, Validyne, Northridge, CA, USA) and signal conditioner (CD-15). The plethysmograph was contained within an infant incubator (model C-86, Isolette, Warminster, PA, USA) in order to maintain the ambient temperature at the approximate nest temperature of 32◦C.

# Results

## **Modulation of respiratory frequency** *in vitro* **by allopregnanolone**

Allopregnanolone had marked effects on respiratory frequency on its own and greatly enhanced the actions of exogenously applied muscimol. Figure 1 illustrates the actions of allopregnanolone (1  $\mu$ M) on respiratory rhythm generated by *in vitro* preparations isolated from P0 rats. The effects of allopregnanolone were time-dependent with a steady-state effect being reached at 10–20 min, and continuing for 30–60 min, which is consistent with previous *in vitro* studies of allopregnanolone actions (Fancsik

*et al.* 2000). The respiratory frequency of brainstem–spinal cord preparations was markedly depressed  $(34 \pm 16\%)$ of control,  $n = 6$ ) by allopregnanolone. In contrast, allopregnanolone caused an increase  $(145 \pm 14\%)$  of control,  $n = 5$ ) of respiratory frequency generated by medullary slice preparations. The amplitude and duration of inspiratory bursts were not changed significantly. The effects of allopregnanolone were antagonized by the GABA<sub>A</sub> receptor antagonist bicuculline (3  $\mu$ M). As demonstrated in Ren & Greer (2006), chloride-mediated conductances are influenced by  $[K^+]_0$  due to the role of potassium ions in the function of the KCC2 chloride-cotransporter (DeFazio *et al.* 2000). Thus, the contrasting actions of allopregnanolone in the two types of *in vitro* preparations can be explained by the fact that the brainstem–spinal cord and medullary slice preparations are bathed in media containing 3 mm and 9 mm  $[K^+]_0$ , respectively.

Our main focus was on the actions of allopregnanolone and DHEAS. However, we screened a variety of neurosteroids' actions *in vitro* and observed that respiratory frequency was modulated by steroid neuromodulators possessing a 3α-hydroxyl group (i.e. allopregnanolone/ $3\alpha$ ,  $5\alpha$ -P, pregnanolone/ $3\alpha$ ,  $5\beta$ -P, alfaxolone/3 $\alpha$ ,5 $\alpha$ -P, allotetrahydro-corticosterone/3 $\alpha$ ,5 $\alpha$ -P), but not a 3 $\beta$ -hydroxyl group (isopregnanolone/3 $\beta$ ,5 $\beta$ -P, pregnenolone/3β-P,  $5\alpha$ -pregnane-3β,20β-diol). Further, the neurosteroids 17β-oestradiol and progesterone had no effects on respiratory frequency at the concentration of 3  $\mu$ M.

# **Developmental changes in the actions of allopregnanolone** *in vivo* **and** *in vitro*

The frequency of breathing in unanaesthetized E20 rats *in vivo* was decreased after 10 min of allopregnanolone administration (4 mg kg<sup>−</sup><sup>1</sup> i.p., Fig. 2*A*). The effects of allopregnanolone were prolonged with a steady-state effect being reached at ∼30 min, continuing for up to one hour. Suppression of breathing was reversed within minutes of the administration of bicuculline (1 mg kg<sup>−</sup>1, i.p., Fig. 2*A*). *In vitro*, respiratory frequency was markedly depressed by bath application of allopregnanolone  $(0.3 \mu)$ . The effects of allopregnanolone were prolonged, continuing for more than 2 h before recovery  $(n=4)$ . However, the suppression of respiratory frequency was rapidly reversed by administration of bicuculline (3 μm, Fig. 2*B*). The effects of allopregnanolone were dose dependent with an  $IC_{50}$  of  $175 \pm 47$  nm (Fig. 2*C*). Figure 2*D* shows

population data for the depression of respiratory frequency *in vitro* and *in vivo* in response to allopregnanolone administration, and the reversal of effects by bicuculline (1 mg kg<sup>−</sup><sup>1</sup> i.p. *in vivo*; 3 μm *in vitro*).

We next examined the age-dependent effects of allopregnanolone *in vivo* and *in vitro* (Fig. 3). Similar to what was observed for the age-dependent effects of chloride-mediated effects (Ren & Greer, 2006), allopregnanolone caused an increase in respiratory frequency in pre-E18 brainstem–spinal cord *in vitro* preparations. From E20 onwards, there was a marked depression of respiratory frequency by allopregnanolone. The depression of respiratory frequency was very pronounced at E20–P0. *In vivo*, there was also a marked





*A*, rectified and integrated suction electrode recordings of C4 ventral root activity in a P0 brainstem–spinal cord preparation bathed in 3 mm  $[K^+]$ <sub>o</sub> showing allopregnanolone-induced depression of respiratory frequency. The effects of allopregnanolone (1  $\mu$ M applied for 10 min indicated by solid line) started at approximately 8 min, and reached a steady-state maximal level at 15 min, continuing for 30 min. The effect of allopregnanolone was antagonized by the presence of bicuculline ( $3 \mu$ M). *B*, rectified and integrated recordings of XII cranial root activity in a medullary slice preparation from a P0 rat, bathed in 9 mm  $[K^+]_0$  showing allopregnanolone-induced increase of respiratory frequency. Similar to that observed in the brainstem–spinal cord preparations, the effects of allopregnanolone (1  $\mu$ M for 10 min) started at approximately 8 min, and reached a steady-state maximal level at 13 min, continuing for 35 min. The effects of allopregnanolone were antagonized by the presence of bicuculline (3  $\mu$ M). *C*, population data from brainstem–spinal cord (SC) and medullary slice preparations showing changes in frequency of respiration relative to control in response to allopregnanolone (Allop, 1  $\mu$ M) in the absence and presence of bicuculline (Bic, 3 μM). Each data point was from five to six P0 preparations. *D*, the depression of respiratory frequency by allopregnanolone (1  $\mu$ M) was increased with the time of the drug application. The maximal effects were achieved with 10 min application of allopregnanolone, since there were no significant further depressing effects observed with 15–30 min. Each data point was from five to eight P0 brainstem–spinal cord preparations. <sup>∗</sup> indicates significant difference relative to control (*P* < 0.05); # indicates significant difference between groups  $(P < 0.05)$ . Results are expressed as mean  $\pm$  standard deviation (s.p.)

depression of respiratory frequency during the perinatal period starting at the earliest age studied, E20. Note that due to lung immaturity, it was not feasible to examine fetal rats at earlier stages of development. Administration of 5–10  $\mu$ l DMSO alone did not affect respiratory frequency.

## **Combined modulatory actions of allopregnanolone and muscimol**

The combined actions of allopregnanolone and muscimol on respiratory frequency were tested using P0 brainstem–spinal cord preparations (Fig. 4*A* and *B*). The respiratory frequency was depressed to  $77 \pm 15\%$  $(n=5)$  of control by 100 nm muscimol. The respiratory rhythm recovered within 5 min of muscimol washout.

Allopregnanolone was then perfused for 20 min and, at a concentration of 60 nm, did not cause a significant depression  $(91 \pm 8\%$  of control,  $n=5$ ) of respiratory frequency. However, after a 20 min preapplication of 60 nm allopregnanolone, the administration of 100 nm muscimol caused a very marked depression of respiratory frequency  $(34 \pm 12\%$  of control,  $n = 5$ ). The respiratory rhythm was not recovered within 20 min  $(n=3)$ , but immediately recovered with application of bicuculline (3  $\mu$ m; returned to 93  $\pm$  8% of control, *n* = 4).

Plethysmographic recordings were performed to examine the interaction of muscimol and allopregnanolone on regulating respiratory frequency *in vivo* (Fig. 4*C* and *D*). The respiratory frequency was depressed to  $81 \pm 12\%$   $(n=4)$  of control by administration of low doses of muscimol (i.p.,



**Figure 2. Depression of respiratory frequency by allopregnanolone** *in vitro* **and** *in vivo*

*A*, whole-body plethysmograph recordings illustrating the allopregnanolone-induced depression of E20 rat breathing frequency. The depression reached a maximum level 40 min after I.P. injection of allopregnanolone and was antagonized by I.P. injection of bicuculline. *B*, rectified and integrated recordings of hypoglossal nerve root activity in the brainstem–spinal cord preparation from an E20 rat. The depression reached a maximum level 20 min after bath application of allopregnanolone (0.3  $\mu$ M for 15 min). The respiratory rhythm stopped for approximately 1 h until administration of bicuculline (3 μM). *C*, dose–response curve for changes in respiratory frequency of brainstem spinal cord preparations in response to 15 min bath application of allopregnanolone (E20). Each data point was from four to eight preparations. *D*, comparison of effects of allopregnanolone (Allop) actions *in vitro* and *in vivo* at E20 in the absence and presence of bicuculline (Bic). Each data point was from four preparations. <sup>∗</sup> indicates significant difference relative to control (*P* < 0.05); # indicates significant difference between groups  $(P < 0.05)$ . Results are expressed as mean  $\pm$  standard deviation (s.p.)

0.3 mg kg<sup>−</sup>1). The respiratory rhythm recovered within 30 min. The respiratory frequency was then depressed to steady-state level  $(85 \pm 10\% \text{ of control}, n=5)$  30 min after i.p. injection of low doses of allopregnanolone  $(0.5 \text{ mg kg}^{-1})$ . The administration of muscimol (I.P., 0.3 mg kg<sup>−</sup>1) caused a further depression of respiratory frequency  $(41 \pm 15\%$  of control,  $n = 4$ ) after 30 min i.p. injection of allopregnanolone  $(0.5 \text{ mg kg}^{-1})$ . The respiratory rhythm was not recovered within 1 h, however, administration of bicuculline ( $i.p., 0.6 mg kg<sup>-1</sup>$ ) immediately returned the breathing frequency toward control value (90  $\pm$  14% of control,  $n = 4$ ).

Recordings from inspiratory neurons in P0 medullary slices bathed in  $3 \text{ mm}$   $[K^+]_0$  and TTX  $(1 \mu)$  were performed to examine the interaction of allopregnanolone and muscimol at the single-cell level (Fig. 5). Note that in the past study (Ren & Greer, 2006) examining chloride-mediated conductances in respiratory neurons, perforated-patch recordings were used to avoid perturbation of normal intracellular [Cl<sup>−</sup>]<sub>i</sub>. However, whole-cell patch recordings sufficed for this study directed at examining the interactions of muscimol and neurosteroids. Application of muscimol (100 nm) caused an  $3.5 \pm 1.3$  mV hyperpolarization from  $V_{\text{rest}}$  of  $-58 \text{ mV}$ , and slight decrease (92  $\pm$  7% of control) in membrane resistance  $(n=7)$ . Administration of 60 nm allopregnanolone on its own (20 min) did not cause significant changes in  $V_m$   $(0.5 \pm 1.1 \text{ mV})$ hyperpolarization) and membrane resistance  $(98 \pm 6\%)$ of control). After a 20 min preapplication of 60 nm allopregnanolone, application of the same dose of muscimol caused an  $8.4 \pm 3.2$  mV hyperpolarization of  $V_m$  and a pronounced decrease (58  $\pm$  11% of control,  $n = 6$ ) in membrane resistance. Bicuculline (3  $\mu$ M,  $n = 5$ ), which did not affect  $V_{\text{rest}}$  or membrane resistance



**Figure 3. Age-dependent effects of allopregnanolone** Results are shown for *in vitro* preparations (300 nm for 15 min application, E17–P4, *•*) and *in vivo* (4 mg kg<sup>−</sup>1, I.P., E20–P4, **❡**). Each data point was from four to eight preparations. \* indicates significant difference relative to control (*P* < 0.05).

on its own, antagonized the effects of muscimol plus allopregnanolone.

#### **Modulation of respiratory rhythm by DHEAS**

As shown in Fig. 6*A*, the inhibition of respiratory rhythm generated by the brainstem–spinal cord preparation caused by muscimol  $(0.3 \mu)$  was antagonized by DHEAS (30  $\mu$ m), a negative modulator of GABA<sub>A</sub> receptor activation. Similarly, DHEAS antagonized the muscimol-induced stimulation of respiratory rhythm generated by the medullary slice preparation bathed in elevated  $[K^+]_0$  (Fig. 6*B*). Administration of DHEAS  $(30 \mu)$  on its own had no significant effects on the frequency of respiratory rhythm in both brainstem–spinal cord and medullary slice preparations. The overall depression of muscimol-induced actions by DHEAS in both types of *in vitro* preparations is plotted in Fig. 6*C*. The IC<sub>50</sub> of 14  $\pm$  3.8  $\mu$ m is similar to that reported from other studies examining DHEAS-mediated inhibition of muscimol-mediated responses *in vitro* (Majewska, 1990; Spivak, 1994; Sousa & Ticku, 1997). Application of the related compound DHEA (10–60  $\mu$ m,  $n = 6$ ) did not modulate muscimol-mediated effects.

Plethysmographic recordings were performed to examine the interaction of muscimol and DHEAS on regulating respiratory frequency *in vivo* (Fig. 6*D* and *E*). Muscimol (0.5 mg kg<sup>−</sup>1) decreased respiratory frequency to 59  $\pm$  15% of control. The muscimol-induced depression of respiratory frequency was reduced to  $86 \pm 12\%$  after administration of 10 mg kg<sup>-1</sup> DHEAS ( $n = 4$ ).

A further demonstration of the interaction of DHEAS and chloride-mediated conductances via  $GABA_A$  receptors is illustrated in Fig. 7. The endogenous level of GABA in the brainstem–spinal cord preparation was elevated using the GABA-uptake inhibitor nipecotic acid (2 mm for 20 min). This caused a marked slowing of respiratory frequency  $(43 \pm 16\%)$  in the brainstem–spinal cord preparation. The effects were due to the combination of actions via  $GABA_A$  and  $GABA_B$  receptors. To minimize the actions via the GABA<sub>B</sub> receptor, an antagonist to that receptor subtype, saclofen (400  $\mu$ m), was added to the superfusate. The remaining depression of respiratory frequency was primarily via GABA<sub>A</sub> receptor-mediated events (63  $\pm$  12%) of control). The further addition of DHEAS (30  $\mu$ M) returned the respiratory frequency toward control values  $(86 \pm 11\%$  of control). In medullary slice preparations, there was a slight, but statistically insignificant, increase in respiratory frequency after 20 min of nipecotic acid application (109  $\pm$  13% of control). However, there was a significant increase (142  $\pm$  11% of control) in respiratory frequency after the administration of saclofen (400  $\mu$ m). The GABAA receptor-mediated increase was diminished  $(115 \pm 10\% \text{ of control})$  by DHEAS (30  $\mu$ M).

## **Depression of muscimol-induced modulation of respiratory activity by DHEAS**

The effects of DHEAS on muscimol-induced outward currents were tested using whole-cell patch recordings of inspiratory neurons under voltage clamp in P1 medullary slices bathed in 3 mm  $[K^+]$ <sub>o</sub> and TTX (1  $\mu$ m) (Fig. 8). With a holding membrane potential  $(V<sub>h</sub>)$  of  $-58$  mV, bath application of muscimol  $(0.3 \mu)$  caused a  $78 \pm 20 \text{ pA}$ 



#### Figure 4. The combined action of allopregnanolone and the GABA<sub>A</sub> receptor agonist muscimol *in vitro* **and** *in vivo*

*A*, rectified and integrated suction electrode recordings of C4 ventral root activity in brainstem–spinal cord preparation from a P0 rat. Traces show the effects of muscimol (Mus) and allopregnanolone (Allop) compared to the combined application of both. The very marked depression of respiratory frequency caused by allopregnanolone and muscimol was blocked by bicuculline (Bic). *B*, population data showing changes in respiratory frequency relative to control for each of the drug protocol administrations shown in *A*. Each data point was from four to five P0 preparations. *C*, whole-body plethysmograph recordings from an unanaesthetized rat pup showing the effects of I.P. administration of muscimol (0.3 mg kg<sup>−</sup>1) or allopregnanolone (0.5 mg kg<sup>−</sup>1). Either agent caused a small depression of breathing. However, when muscimol (I.P., 0.3 mg kg<sup>-1</sup>) was administered 30 min after I.P. injection of allopregnanolone (0.5 mg kg<sup>-1</sup>) (trace 4), a period of apnoea occurred. The depression of respiratory frequency caused by muscimol and allopregnanolone was antagonized by bicuculline (0.6 mg kg<sup>−</sup>1). *D*, population data showing changes in respiratory frequency relative to control for each of the drug protocol administrations shown in *C*. Each data point was from four P0 preparations. <sup>\*</sup> indicates significant difference relative to control (*P* < 0.05); # indicates significant difference between groups (*P* < 0.05). Results are expressed as mean ± standard deviation (S.D.)





*A*, whole-cell patch clamp recording from an inspiratory neuron in a P0 medullary slice preparation bathed in 3 mM  $[K^+]$ <sub>o</sub> and TTX (1  $\mu$ M). The muscimol (Mus)-induced hyperpolarization and decrease in input resistance (determined by application of hyperpolarizing current pulses) were amplified in the presence of allopregnanolone (Allop). These effects were antagonized by bicuculline (bic). *B*, population data showing a hyperpolarizing response for each of the drug applications shown in *A*. Each data point was from five to seven P0 preparations. # indicates significant difference between groups ( $P < 0.05$ ). Results are expressed as mean  $\pm$  standard deviation (s.p.)

outward current ( $n = 5$ ). The muscimol-induced outward current was reduced to  $21 \pm 14$  pA in the presence of bath-applied DHEAS (30  $\mu$ m). DHEAS (30  $\mu$ m) on its own did not cause any significant current. Reapplication of muscimol after washout of DHEAS induced a  $65 \pm 22$  pA. outward current.

#### Discussion

Past work has demonstrated that circulating sex hormones progesterone and testosterone stimulate breathing (Behan *et al.* 2003). Here, we focus on respiratory modulation by. neurosteroids synthesized *de novo* in glial and neuronal



#### **Figure 6. Effects of DHEAS on muscimolinduced changes of respiratory frequency** *in vitro* **and** *in vivo*

*A*, rectified and integrated suction electrode recordings of C4 ventral root activity in a P0 brainstem–spinal cord preparation. The inhibition of respiratory frequency by muscimol (Mus) was antagonized by DHEAS. *B*, rectified and integrated suction electrode recordings of XII nerve roots in a P0 medullary slice preparation. The muscimol-induced increase of respiratory frequency in 9 mm  $[K^+]_0$  bathing solution was antagonized by DHEAS. *C*, dose–response curve for the DHEAS blockade of muscimol-induced effects of respiratory frequency in brainstem–spinal cord and medullary slice preparations. Each data point was from five to eight P0 preparations. *D*, the effects of I.P. administration of muscimol (0.5 mg kg<sup>−</sup>1) to an unanaesthetized P0 rat pup. The muscimol-induced depression of breathing was antagonized by DHEAS (10 mg kg<sup>−</sup>1). *E*, population data showing changes in respiratory frequency relative to control for each of the drug protocol administrations shown in *D*. Each data point was from four P0 preparations. \* indicates significant difference relative to control  $(P < 0.05)$ ; # indicates significant difference between groups (*P* < 0.05). Results are expressed as mean  $\pm$  standard deviation (s.p.)



**Figure 7. The effects of DHEAS on the changes of respiratory frequency caused by elevated levels of endogenous GABA**

*A*, rectified and integrated suction electrode recordings of C4 ventral root in P0 brainstem–spinal cord (SC) (left panel) and XII nerve root activity in P0 medullary slice (right panel) preparations. Endogenous levels of GABA were elevated by bath application of the GABA uptake inhibitor nipecotic acid (Nip). This resulted in a clear decrease in respiratory frequency of brainstem–SC preparations and a slight, but insignificant increase in medullary slice preparations after 20 min of nipecotic acid application. The antagonist to GABAB receptor, saclofen (Sac), was added to the bathing medium to minimize the component of the respiratory frequency depression resulting from the actions of GABA<sub>B</sub> receptors. The remaining GABA<sub>A</sub> receptor-mediated decrease and increase of respiratory frequency in brainstem–spinal cord and medullary slice preparations, respectively, was depressed by DHEAS. *B*, population data showing changes in respiratory frequency relative to control for *in vitro* preparations exposed to the drug paradigms shown in *A*. Each data point was from four P0 preparations. <sup>∗</sup> indicates significant difference relative to control (*P* < 0.05); # indicates significant difference between groups (*P* < 0.05). Results are expressed as mean  $\pm$  standard deviation (s.p.)

cells, which begin to express the necessary enzymes for this biochemical process early in development (Mellon & Vaudry, 2001). Neurosteroids interact with the  $GABA_A$ receptor and modulate GABAergic activity (Majewska *et al.*1986). Data from this study demonstrate that the overall efficacy of GABA<sub>A</sub>-mediated modulation of respiratory frequency can be markedly regulated by their presence. Specifically, allopregnanolone and DHEAS are positive





A, whole-cell patch clamp recording from an inspiratory neuron in a P1 medullary slice preparation bathed in 3 mm  $[K^+]$ <sub>o</sub> and TTX (1 µM). The neuron was clamped at  $-58$  mV in voltage-clamp mode, and the outward current caused by bath application of muscimol (Mus) recorded. The muscimol-induced current was depressed by bath application of DHEAS (30 μM) and recovered after 5 min washout of DHEAS. *B*, population data showing the amplitude of outward current measured in response to muscimol (Mus) and muscimol plus DHEAS. Each data point was from five P1 preparations. # indicates significant difference between groups (*P* < 0.05). Results are expressed as mean  $\pm$  standard deviation (s.p.)

and negative modulators of the GABAA receptor function on respiratory neurons, respectively, during the perinatal period.

In a related study, we determined the actions of chloride-mediated conductances on respiratory rhythmogenesis in perinatal rats from the time of inception of fetal inspiratory drive through to the newborn period (Ren & Greer, 2006). The transition from excitatory to inhibitory effects on respiratory rhythmogenesis occurs at approximately E19. By birth, GABA induces a hyperpolarization of the membrane potential in respiratory medullary neurons, and a suppression of respiratory frequency. The age-dependent change in the actions of chloride-mediated conductances is regulated by the development of chloride cotransporters (KCC2 and NKCC1).

Allopregnanolone potentiates the actions of GABA and, at higher concentrations, directly gates the  $GABA_A$ receptor chloride channel at a site distinct from the GABA-binding site (Callachan *et al.* 1987; Majewska, 1992; Lambert *et al.* 1996; Ueno *et al.* 1997; Rupprecht & Holsboer, 2000). The excitability of respiratory neurons in the ventrolateral medulla of perinatal rodents is clearly affected by allopregnanolone on its own, and at more physiological levels in the nanomolar range there was a clear accentuation of muscimol-induced currents. Data from brainstem–spinal cord preparations show a transition from excitatory to inhibitory action of allopregnanolone at E19. This is similar to the transition observed for the effects of the  $GABA_A$  receptor agonist muscimol (Ren & Greer, 2006). The post-E19 suppression of respiratory frequency by allopregnanolone was particularly pronounced from E20–P0; also similar to what was observed for muscimol-induced actions. This may reflect developmental changes in  $GABA_A$  receptor subunit composition, density and/or distribution within the somata and dendritic membranes. The suppression of respiratory frequency by allopregnanolone was also observed *in vivo*. In all experimental models, the allopregnanolone-mediated actions were countered by the  $GABA<sub>A</sub>$  receptor antagonist bicuculline. The seemingly paradoxical effects of increased respiratory rhythm by allopregnanolone in the medullary slice preparation can be accounted for by elevated level of  $[K^+]_0$  in the media used to bathe the preparation (see Ren & Greer, 2006). Specifically,  $[K^+]_0$  influences the function of cotransporters that determine transmembrane Cl<sup>−</sup> gradients, and thus the net effect of chloride-mediated conductances through the GABAA receptor.

The physiological relevance of allopregnanolone actions for the control of respiration during the perinatal period is significant. The levels of allopregnanolone and steroidogenic enzymes are particularly high in the brain during the perinatal period (Brown & Papadopoulos, 2001; Mellon & Vaudry, 2001). They are markedly increased further by a variety of stressors including hypoxia, asphyxia, parturition, ethanol exposure and infection; possibly as a neuroprotectant response to prevent excessive excitation (Morrow *et al.* 1999; Brown & Papadopoulos, 2001; Billiards *et al.* 2002; Nguyen *et al.* 2003, 2004). This raises the distinct possibility that neurosteroids depress, in a state-dependent manner, respiratory drive in perinatal mammals. For example, an elevation of allopregnanolone and GABA (Hoop *et al.* 1999) levels during hypoxia, and their combined actions could lead to a profound depression of respiratory drive. The precedent for neurosteroid modulation of respiration comes from a previous study demonstrating the suppression of fetal breathing methods (FBM) in sheep by infusion of pregnanolone (Nicol *et al.* 1999).

DHEAS belongs to the class of neurosteroids that acts to depress the effects of GABA<sub>A</sub> receptor ligands. Further it may play a role in neurodevelopment, due to a transient expression of its synthesizing enzyme (Compagnone *et al.* 1995) and the potential ability of DHEAS to aid in neuronal pathway formation (Compagnone & Mellon, 1998). Data from this study indicate that DHEAS suppressed the inhibition of respiratory frequency caused by  $GABA_A$  receptor activation either by muscimol or by accentuating the endogenous levels of GABA. It should be noted that DHEAS can also act as a positive modulator of sigma1 and NMDA receptors (Monnet & Maurice, 2006); the implications for those actions on respiratory modulation were not investigated in this study.

In summary, these data should be considered in context with those from a recent study demonstrating the actions of chloride-mediated conductances, including those via GABAA receptors, on respiratory frequency during the perinatal period (Ren & Greer, 2006). Specifically, the net effect of GABA acting via GABA<sub>A</sub> receptors will be determined by the overall balance of negative and positive neurosteroid modulators within respiratory nuclei. This adds a level of complexity that must be considered when examining the depression of breathing in mammals associated with various behavioural states and pathogenic conditions such as apnoea and sudden death suspected to be associated with central respiratory dysfunction.

# References

- Akwa Y, Young J, Kabbadj K, Sancho MJ, Zucman D, Vourch C, Jung-Testas I, Hu ZY, Le Goascogne C & Jo DH (1991). Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. *J Steroid Biochem Mol Biol* **40**, 71–81.
- Angulo Y Gonzalez AW (1932). The prenatal growth of the ´ albino rat. *Anat Record* **52**, 117–138.
- Barbaccia ML, Serra M, Purdy RH & Biggio G (2001). Stress and neuroactive steroids. *Int Rev Neurobiol* **46**, 243–272.

Baulieu EE (1997). Neurosteroids: of the nervous system, by the nervous system, for the nervous system. *Recent Prog Horm Res* **52**, 1–32.

Baulieu EE & Robel P (1996). Dehydroepiandrasterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. *J Endocrinol* **150**, S221–239.

Baulieu EE & Robel P (1998). Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. *Proc Natl Acad Sci U S A*, **95**, 4089–4091.

Behan M, Zabka AG, Thomas CF & Mitchell GS (2003). Sex steroid hormones and the neural control of breathing. *Respir Physiol Neurobiol* **136**, 249–263.

Billiards SS, Walker DW, Canny BJ & Hirst JJ (2002). Endotoxin increases sleep and brain allopregnanolone concentrations in newborn lambs. *Pediatr Res* **52**, 892–899.

Brockhaus J & Ballanyi K (1998). Synaptic inhibition in the isolated respiratory network of neonatal rats. *Eur J Neurosci* **10**, 3823–3839.

Brown RC & Papadopoulos V (2001). Role of the peripheraltype benzodiazepine receptor in adrenal and brain steroidogenesis. *Int Rev Neurobiol* **46**, 117–143.

Callachan H, Cottrell GA, Hather NY, Lambert JJ, Nooney JM & Peters JA (1987). Modulation of the GABAA receptor by progesterone metabolites. *Proc R Soc Lond B Biol Sci* **231**, 359–369.

Compagnone NA, Bulfone A, Rubenstein JL & Mellon SH (1995). Steroidogenic enzyme P450c17 is expressed in the embryonic central nervous system. *Endocrinology* **136**, 5212–5223.

Compagnone NA & Mellon SH (1998). Dehydroepiandrosterone: a potential signalling molecule for neo cortical organization during development. *Proc Natl Acad Sci U S A* **95**, 4678–4683.

DeFazio RA, Keros S, Quick MW & Hablitz JJ (2000). Potassium-coupled chloride cotransport controls intracellular chloride in rat neocortical pyramidal neurons. *J Neurosci* **20**, 8069–8076.

Fancsik A, Linn DM & Tasker JG (2000). Neurosteroid modulation of GABA IPSCs is phosphorylation dependent. *J Neurosci* **20**, 3067–3075.

Gizerian SS, Morrow AL, Lieberman JA & Grobin AC (2004). Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats. *Brain Res* **1012**, 66–74.

Greer JJ, Smith JC & Feldman JL (1992). Generation of respiratory and locomotor patterns by an *in vitro* brainstem– spinal cord fetal rat preparation. *J Neurophysiol* **67**, 996–999.

Hoffman SW, Virmani S, Simkins RM & Stein DG (2003). The delayed administration of dehydroepiandrosterone sulfate improves recovery of function after traumatic brain injury in rats. *J Neurotrauma* **20**, 859–870.

Hoop B, Beagle JL, Maher TJ & Kazemi H (1999). Brainstem acid neurotransmitters and hypoxic ventilatory response. *Respir Physiol* **118**, 117–129.

Huang J, Suguihara C, Hehre D, Lin J & Bancalari E (1994). Effects of GABA receptor blockage on the respiratory response to hypoxia in sedated newborn piglets. *J Appl Physiol* **77**, 1006–1010.

Joels M (1997). Steroid hormones and excitability in the mammalian brain. *Frontiers Neuroendocrinol* **18**, 2–48.

Johnson SM, Smith JC & Feldman JL (1996). Modulation of respiratory rhythm *in vitro*: role of Gi/o protein-mediated mechanisms. *J Appl Physiol* **80**, 2120–2133.

Jung-Testas I & Baulieu EE (1998). Steroid hormone receptors and steroid action in rat glial cells of the central and peripheral nervous system. *J Steroid Biochem Mol Biol* **65**, 243–251.

Lambert JJ, Belelli D, Hill-Venning C, Callachan H & Peters JA (1996). Neurosteroid modulation of native and recombinant GABAA receptors. *Cell Mol Neurobiol* **16**, 155–174.

Majewska MD (1990). Steroid regulation of the GABA<sub>A</sub> receptor: ligand binding, chloride transport and behaviour. *Ciba Found Symp* **153**, 83–106.

Majewska MD (1992). Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. *Prog Neurobiol* **38**, 379–395.

Majewska MD, Harrison NL, Schwartz RD, Barker JL & Paul SM (1986). Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* **232**, 1004–1007.

Mellon SH (1994). Neurosteroids: biochemistry, models of action, and clinical relevance. *J Clin Endocrinol Metab* **78**, 1003–1008.

Mellon SH & Vaudry H (2001). Biosynthesis of neurosteroids and regulation of their synthesis. *Int Rev Neurobiol* **46**, 33–78.

Monnet FP & Maurice T (2006). The sigma1 protein as a target for the non-genomic effects of neuro(active) steroids: molecular, physiological, and behavioral aspects. *J Pharmacol Sci* **100**, 93–118.

Morrow Al Janis GC, VanDoren MJ, Matthews DB, Samson HH, Janak PH & Grant KA (1999). Neurosteroids mediate pharmacological effects of ethanol: a new mechanism of ethanol action? *Alcohol Clin Exp Res* **23**, 1933–1940.

Nguyen PN, Gilliares SS, Wlaker DW & Hirst JJ (2003). Changes in 5α-pregnane steroids and neurosteroidogenic enzyme expression in the perinatal sheep. *Pediatr Res* **53**, 956–964.

Nguyen PN, Yan EB, Castillo-Melendez M, Walker DW & Hirst JJ (2004). Increased allopregnanolone levels in the fetal sheep brain following umbilical cord occlusion. *J Physiol* **560**, 593–602.

Nicol MB, Hirst JJ & Walker D (1999). Effects of pregnanolone on behavioural parameters and the responses to GABA(A) receptor antagonists in the late gestation fetal sheep. *Neuropharmacol* **38**, 49–63.

Park-Chung M, Malayev A, Purdy RH, Gibbs TT & Farb DH (1999). Sulfated and unsulfated steroids modulate GABA-A receptor function through distinct sites. *Brain Res* **830**, 72–87.

Rekling JC & Feldman JL (1998). Pre-Botzinger complex and pacemaker neurons: hypothesized site and kernel for respiratory rhythm generation. *Annu Rev Physiol* **60**, 385–405.

Ren J & Greer JJ (2006). Modulation of respiratory rhythmogenesis by chloride mediated conductances during the perinatal period. *J Neurosci* **26**, 3721–3730.

Ritter B & Zhang W (2000). Early postnatal maturation of GABAA-mediated inhibition in the brainstem respiratory rhythm-generating network of the mouse. *Eur J Neurosci* **12**, 2975–2984.

- Rupprecht R & Holsboer F (2000). Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. *Trends Neurosci* **22**, 410–416.
- Shao XM & Feldman JL (1997). Respiratory rhythm generation and synaptic inhibition of expiratory neurons in pre-Botzinger complex: differential roles of glycinergic and GABAergic neural transmission. *J Neurophysiol* **77**, 1853–1860.
- Smith JC, Ellengerger HH, Ballanyi K, Richter DW & Feldman JL (1991). Pre-Botzinger complex: a brainstem region that may generate respiratory rhythm in mammals. *Science* **254**, 726–728.
- Smith JC, Greer JJ, Liu G & Feldman JL (1990). Neural mechanisms generating respiratory pattern in mammalian brainstem-spinal cord *in vitro*. I. Spatiotemporal patterns of motor and medullary neuron activity. *J Neurophysiol* **64**, 1149–1169.
- Sousa A & Ticku MK (1997). Interactions of the neurosteroid dehydroepiandrosterone sulfate with the GABAA receptor complex reveals that it may act via the picrotoxin site. *J Pharmacol Exp Ther* **282**, 827–833.
- Spivak CF (1994). Desensitization and noncompetitive blockade of GABA<sub>A</sub> receptors in ventral midbrain neurons by a neurosteroid dehydroepiandrosterone sulfate. *Synapse* **16**, 113–122.
- Ueno S, Bracamontes J, Zorumski C, Weiss DS & Steinbach JH (1997). Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor. *J Neurosci* **17**, 625–634.

# **Acknowledgements**

The research was funded by grants from the Toronto Hospital for Sick Children Foundation, Alberta Lung Association (ALA) and the Canadian Institutes of Health (CIHR). J.J.G. is a Scientist of the Alberta Heritage Foundation for Medical Research (AHFMR) and J.R. is a recipient of CIHR-SIDS, CIHR-CLA and AHFMR Fellowships.